SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (15108)2/14/1998 7:46:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Stan, Breast Cancer chemoprevention is certainly a possibility (as initially described in the first post on this board and subsequently published over a year ago). However, I would not expect a prevention trial to begin before Targretin was approved for breast cancer treatment.

It will be interesting to see if there is any data on the Phase I combination trial of Panretin and Tamoxifen (in human breast cancer, of course).



To: squetch who wrote (15108)2/14/1998 7:49:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
I believe that LGND has the cancer rights to Targretin (with a royalty to AGN). I'm not sure about Targretin combined with a LLY SERM (such as Evista), which is part of the research arm ($49 million over 5 years) of the $200 million mega deal.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News